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Coenzyme A is moRe ThAn ‘jusT ’  A meTABoliC CofACToR
In all organisms, there are various metabolites that play a vital role to enable proper 
cellular metabolic processes. The human metabolome comprises a total of more than 
25,000 identified endogenous metabolites1. Such biological molecules or metabolites, 
mainly vitamins, amino acids, lipids, carbohydrates, nucleic acids, and nucleotides, are 
involved in important biological pathways and metabolic circuits1-3. Alteration of metabolite 
homeostasis disrupts the physiology of cells, leading to various diseases2. Recent studies 
advance our understanding that some metabolites are not only involved in cellular 
metabolism, but also have other molecular functions. It has become evident that similar 
to multifunctional ‘moonlighting proteins’, ‘moonlighting metabolites’ also exists. For 
example, nicotinamide adenine dinucleotide (-NAD) was shown to regulate metabolism 
and also sirtuin deacetylase activity. This direct dual role of NAD could not be anticipated 
initially4,5. Recent findings now also indicate that CoA, another metabolic cofactor, can be 
considered as being more than ‘ just’ a metabolic cofactor, and altered CoA levels lead to 
severe and complex effects. 
The importance of CoA and acyl-CoA in essential metabolic pathways like Kreb’s cycle 
and fatty acid β-oxidation was previously well-studied6. However, the role of acetyl-CoA in 
protein post-translational modification emerged more recently as an interesting focus in 
biological sciences7. Cellular citrate and pyruvate levels are primarily considered to regulate 
acetyl-CoA levels7,8. Whereas the CoA biosynthesis pathway is crucial for the maintenance 
of free CoA levels, which subsequently can be converted into acetyl-CoA and thereby can 
serve, as an acetyl source. In addition to the influence of CoA levels on metabolism and 
protein-acetylation levels, recently the metabolic cofactor CoA has shown to influence 
other cellular functions as well. It was demonstrated that CoA can bind directly to calcium/
calmodulin-dependent protein kinase II (CaMKII) and thereby activates CAMKII in Xenopus 
leavis oocytes promoting oocyte survival via phosphorylation and inactivation of caspase-29. 
Moreover, evidence is presented that this is a conserved mechanism which is also present 
in mammalian oocytes9. These data reveal a signaling function of CoA independent from its 
role in cellular metabolism (Figure 1). 
Based on the initial discoveries and the recent evidence of diverse CoA regulated cellular 
processes, it is evident that the maintenance of proper cellular CoA biosynthesis is vital. 
However, there is a lack of detailed research studies to understand the consequences of 
impaired de novo CoA biosynthesis. Here in this chapter, we will address the important 
findings presented in this thesis about consequences of impairment of the CoA biosynthesis 
pathway and also we will discuss how this is related to the pathophysiology of Pantothenate 
Kinase-Associated Neurodegeneration. 
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Figure 1: Schematic representation of diverse roles of CoA in cellular physiology. 
 
Based on the initial discoveries and the recent evidence of diverse CoA regulated cellular 
processes, it is evident that the maintenance of proper cellular CoA biosynthesis is vital. 
However, there is a lack of detailed research studies to understand the consequences of 
impaired de novo CoA biosynthesis. Here in this chapter, we will address the important 
findings presented in this thesis about consequences of impairment of the CoA biosynthesis 
pathway and also we will discuss how this is related to the pathophysiology of Pantothenate 
Kinase-Associated Neurodegeneration.  
 
Coenzyme A biosynthesis pathway and neurodegenerative diseases 
 
The de novo CoA biosynthesis is carried out by the action of specific enzymes in several steps 
starting from pantothenate10. Pantothenate is present in sufficient quantities in the diet, and 
bacteria in human intestines also produce it. The enzymatic steps of the canonical CoA de 
novo biosynthesis route are well conserved and genes encoding for these enzymes have 
been identified in various organisms11-16. CoA regained new attention after the discovery 
that one of the CoA biosynthetic enzymes ‘pantothenate kinase’ (or PANK) was found to 
cause a neurodegenerative disease characterized with very specific features. After the 
discovery of the causative gene ‘pantothenate kinase 2’ in 2001, the disease was named 
Pantothenate Kinase-Associated Neurodegeneration (PKAN)17.  
Figure 1: Schematic representation of diverse roles of CoA in cellular physiology.
Coenzyme A biosynthesis pathway and neurodegenerative diseases
The de novo CoA biosynthesis is carried out by the acti n of sp cific enzymes in everal steps 
starting from pantothenate10. Pantothenate is present in sufficient quantities in the diet, and 
bacteria in human intestines also produce it. The enzymatic steps of the canonical CoA de 
novo biosynthesis route are well conserved and genes encoding for these enzymes have 
been identified in various organisms11-16. CoA regained new attention after the discovery that 
one of the CoA biosynthetic enzymes ‘pantothenate kinase’ (or PANK) was found to cause 
a neurodegenerative disease characterized with very specific features. After the discovery 
of the ausative gene ‘pantothenate kinase 2’ in 2001, the disease was named Pantothenate 
Kinase-Associated Neurodegeneration (PKAN)17. 
PKAN is a subform of Neurodegeneration with Brain Iron Accumulation (NBIA), which is a 
group of disorders all characterized by iron accumulation in the brain18. Mutations in several 
seemingly unrelated genes (including pantothenate kinase 2) leads to a specific subform of 
NBIA19,20. PKAN patients show the clinical manifestation of a progressive loss of extrapyramidal 
and pyramidal functions, and patients also often suffer from dystonia, dysarthria, and 
intellectual disabilities21. The identification of the causative gene for PKAN indicated a clear 
link between neurodegeneration and CoA de novo biosynthesis and suggests that the intact 
h meostasis of CoA levels is highly es ntial for ormal brain funct on. Howev r, to date, the 
pathophysiology of this disease is largely unknown, a therapy is lacking and how impaired de 
novo biosynthesis of CoA leads to a specific subform of NBIA is still unclear. 
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Drosophila to understand the link between Coenzyme A and 
neurodegeneration
In order to investigate functions of CoA and consequences of impaired de novo CoA 
biosynthesis, several model organisms have been used, such as Arabidopsis thaliana22, 
mice23,24, Schizosaccharomyces pombe25 and Drosophila melanogaster11,14,26. Here we will 
focus on the multicellular eukaryote model organism Drosophila melanogaster (fruit fly) 
and its potential aid in understanding the link between CoA and neurodegeneration will be 
summarized and discussed. 
In 2001, a few months before PANK2 was identified as the causative gene for PKAN, 
Wasserman and coworkers described the phenotype of Drosophila melanogaster carrying 
mutations in the gene fumble, coding for pantothenate kinase11. The fumble gene is 
also referred to as dPANK/fbl (Drosophila pantothenate kinase/fumble)11. Although the 
researchers focused in this study on the male sterile phenotype, they also noticed the 
locomotor impairment of the mutant flies. Subsequently, they named the gene and the 
mutant after this locomotive phenotype; ‘fumble’. Wasserman and co-workers, therefore, 
were the first who revealed the link between impaired pantothenate kinase function and 
locomotor abnormalities. In addition to the locomotor defects, in dPANK/fbl mutant flies a 
decreased number of mitotic neuroblasts and an increase in abnormal (lagging chromosomes 
and anaphase bridges) mitotic chromosomes were observed11. In addition, spermatocytes of 
dPANK/fbl mutant flies also showed defects in cytokinesis and chromosome segregation. 
Nevertheless, why mutations in dPANK/fbl lead to such specific phenotypes is not known yet. 
Later in the same year, the Hayflick laboratory identified human PANK2 as a causative gene 
for the severe autosomal recessive neurodegenerative disorder PKAN, further establishing a 
link between impaired CoA biosynthesis and abnormal locomotor functions17. However, PKAN 
is still surrounded by unresolved basic questions, such as: why do patients with mutations 
in PANK2 suffer from neurological symptoms, what are the mechanisms behind the specific 
symptoms and why is especially the nervous system affected? 
Drosophila melanogaster is a versatile and genetically manipulatable model organism. 
It is widely used to study basic mechanisms in life sciences at various levels (molecular, 
cellular, tissue, developmental and behavioral) and it is also used as a model to study human 
diseases27-29. Similarly to many diseases with a genetic cause, a Drosophila PKAN model 
was explored, and dPANK/fbl mutants were further investigated to understand the link 
between neurodegeneration and CoA biosynthesis. Firstly, the Drosophila genes coding for 
enzymes required for the de novo biosynthesis of CoA were annotated by in-silico analysis 
and 5 Drosophila loci were identified coding for structural orthologs of PANK (dPANK/fbl), 
PPCS (dPPCS), PPCDC (dPPCDC) and a bifunctional PPAT-DPCK (dPPAT-DCPK; also called 
dCOASY) and a single dDPCK14. Moreover, it has been shown that Drosophila mutants carrying 
mutations in dPANK/fbl, dPPCS and dPPAT-DCPK show a comparable phenotype, strongly 
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suggesting that impaired CoA biosynthesis causes this shared phenotype14. All mutants show 
abnormal locomotor function (impaired climbing and flying behavior) which worsens upon 
ageing, a decreased life span, abnormal lipid homeostasis, increased sensitivity to Reactive 
Oxygen Species (ROS) inducing agents, increased apoptotic cells in the brain and increased 
sensitivity to DNA damaging agents14. Moreover, consistent with the previous results from 
Wasserman and co-workers11 all investigated Drosophila CoA mutants show increased number 
of cells with abnormal mitotic chromosomes in larval brains. The phenotypes of all Drosophila 
CoA mutants were comparable. However, the severity of the phenotypes varied between the 
mutants, most likely because the mutants are hypomorphs, and, therefore, the rest-activity 
of each affected enzyme may be different. 
The use of Drosophila dPANK/fbl mutant made it possible for us to investigate whether 
the impaired function of dPANK/fbl actually leads to decreased levels of CoA. If so, this 
would suggest that decreased levels of the end product CoA is the primary cause of the 
reported defects. To investigate whether CoA biosynthesis is affected, we first measured 
CoA levels in both dPANK/fbl fly mutants and also in dPANK/fbl (by RNA-interference) 
depleted Drosophila cultured cells. The results presented in this thesis evidently shows 
that impaired dPANK/fbl activity leads to decreased levels of total CoA (Chapter 2)30. 
More interestingly, in a selective compound screening, pantethine was found to replenish 
the decreased CoA levels and thereby partly rescued life span, neurodegeneration and 
locomotor defects in dPANK/fbl mutant flies (Chapter 2)30. These data were the first to 
suggest that decreased levels of CoA may be causative of the observed neurodegenerative 
symptoms using a eukaryotic PKAN model system. These results also suggested that patients 
who carry mutations in other CoA biosynthesis enzymes may also suffer from a comparable 
disorder like PKAN. Indeed, the recent finding that the mutation in the gene coding for the 
last enzyme in the CoA biosynthesis pathway, PPAT-DPCK or Coenzyme A synthase (COASY), 
causes a new form of NBIA, referred to as CoPAN, further indicated that impairment of 
CoA homeostasis is strongly associated with neurodegeneration31. More detailed research 
needs to be performed to investigate whether the affected brain regions in PKAN and 
CoPAN show decreased CoA levels. Like vitamin-B5, Pantethine is also a known substrate for 
pantothenate kinase. Nevertheless, the restoration of decreased CoA levels in dPANK/fbl 
mutants with pantethine indicated a possible PANK-independent alternative route parallel to 
the canonical de novo CoA biosynthesis route (Chapter 2; Figure 2)30. Moreover, vitamin-B5 
did not rescue the dPANK/fbl mutant phenotype. These results indicate the presence of 
an unknown kinase able to phosphorylate pantetheine, or suggests the possibility that the 
residual PANK enzyme present in the hypomorph dPANK/fbl mutants is having a high affinity 
to pantethine. More detailed research is therefore needed to understand the working 
mechanism of pantethine. 
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PKAN and CoPAN in relation to mitochondrial integrity
The next question that arises is: how do decreased levels of CoA lead to neurodegeneration? 
It is yet unresolved whether decreased levels of CoA only cause metabolic defects or also 
lead to defects in non-metabolic processes in cells. Studies in mice showed that decreased 
levels of CoA influence the metabolic state of an organism23,32-35. Therefore, the most likely 
underlying cause of PKAN and CoPAN is speculated to be abnormal metabolic reactions. 
The link between impaired cellular metabolism, mitochondrial dysfunction and severity 
of many neurodegenerative diseases is broadly recognized36-38. However, the debate of 
whether mitochondrial dysfunction is a primary cause or consequence of neurodegeneration 
remains. PKAN and CoPAN share similarities regarding mitochondria. The mitochondrial 
localization of both PANK2 and COASY suggests that mutations in PANK2 and COASY, lead to 
impaired mitochondrial function, and this may lead in turn to neurodegeneration31,39,40. Our 
research data listed in this thesis also revealed that in both dPANK/fbl mutant flies and also in 
dPANK/fbl depleted cultured Drosophila cells, mitochondria are severely affected (chapter 
2) 30. Moreover, it was also demonstrated that PANK2 downregulation in the human cell line 
(HEK293), resulted in impaired mitochondrial activity (chapter 2)30. These results are in-line 
with the recent studies performed in mice. HoPan treatment induced both CoA depletion 
and severely swollen mitochondria in the mice liver35. Moreover, in neurons derived from 
PANK2 KO mice, swollen mitochondria and defects in mitochondrial membrane potential 
were reported41. Concisely, all the above information strongly corroborated the link between 
PKAN and mitochondrial dysfunction. However, whether such a link also exist in CoPAN 
needs yet to be verified. Moreover, the impairment in CoA biosynthesis can also affect other 
functions independent of mitochondrial dysfunction.
Coenzyme A and its influence on protein-acetylation levels
The influence of altered CoA homeostasis on other than metabolic reactions became 
evident by a series of experiments, demonstrating that acetyl-CoA levels influenced protein 
acetylation. Acetyl-CoA provides the acetyl group, which is necessary for acetylation of 
proteins mediated by acetyltransferases (HAT/KAT’s). Protein-acetylation is a post-translational 
modification influencing protein functions to a large extend42,43. In Saccharomyces cerevisiae 
or budding yeast, it is reported that acetyl-CoA synthetase mutants have decreased levels 
of histone acetylation44. Reduced levels of acetyl-CoA evoked by inactivation of the budding 
yeast ortholog of AMP-activated protein kinase (AMPK) also resulted in decreased histone 
acetylation, reduced fitness and stress resistance45. In addition, two recent studies also 
showed a link between acetyl-CoA and autophagy. In budding yeast, it was demonstrated 
that acetyl-CoA is a suppressor of autophagy and down-regulation of acetyl-CoA synthetase 
in flies enhanced autophagy and increased life span46. The second manuscript showed in 
mice and human cells that starvation resulted in decreased levels of acetyl-CoA, a reduction 
of acetylation of cytoplasmic proteins and induction of autophagy47. When acetyl-CoA 
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levels were manipulated under these conditions and kept at a higher level, autophagy was 
suppressed. This suppression of autophagy was dependent on EP300 acyltransferase activity, 
suggesting acetyl-CoA levels regulate EP300 activity47. Acetyl-CoA levels can also influence 
cell cycle progression because, in budding yeast, it was demonstrated that acetyl-CoA 
promotes acetylation of histones in the regulatory domain of the G1 cyclin CLN3 and cell 
cycle progression is promoted48. Acetyl-CoA levels are not the only influencing factor for 
protein acetylation, as manipulating CoA levels itself can also regulate protein acetylation 
levels. We showed evidence that the decrease in CoA levels in both Drosophila in vitro and 
in vivo PANK model systems are associated with decreased levels of histone and tubulin 
acetylation. Moreover, restoration of CoA levels with pantethine reverted this phenotype 
(chapter 3; Figure 2)49. Together these data indicated a strong link between CoA and/or 
acetyl-CoA in regulating acetylation of specific proteins.
Link between decreased histone and tubulin acetylation and 
neurodegeneration
Decreased histone and tubulin acetylation levels are associated with neurodegenerative 
diseases, and, therefore, the decreased levels of protein acetylation may explain part of the 
neurodegenerative phenotype of dPANK/fbl mutant flies. There is a strong link between 
cognitive function, motor neuron function, and histone acetylation50,51. Fewer but nonetheless 
compelling studies reported the association between tubulin acetylation and neuronal function. 
Tubulin hyperacetylation protects against axonal degeneration52 and tubulin acetylation is 
required for the touch response in C.elegans (chapter 3)49. In APPPS1-21 mice (a mouse model 
for Alzheimer’s disease), levels of acetylated tubulin are decreased and restored in the presence 
of knockdown of the deacetylase Hdac6. In these APPPS1-21-Hdac6-/- mice improvement of 
associative and spatial memory is observed compared to APPPS1-21 mice53.
These data showed that the proper neuronal function requires normal levels of tubulin 
and histone acetylation. Therefore, the decreased levels of histone and tubulin acetylation, as 
observed in the dPANK/fbl mutants, could partly explain the neurodegenerative phenotype. 
The addition of valproic acid restored the decreased histone and tubulin acetylation levels and 
partly restored the locomotor function of mutant dPANK/fbl larvae, suggesting that impaired 
acetylation also underlies the observed phenotypes (chapter 3)49. dPANK/fbl mutants also 
show increased sensitivity to DNA damaging and increased accumulation of DNA damage14. The 
impairment in histone acetylation could also explain such increased sensitivity, as acetylation of 
histones regulates DNA damage responses in various organisms43,54-58. In dPANK/fbl depleted 
cultured Drosophila cells, after ionizing radiation, kinetics of histone acetylation are abnormal 
compared to control cells, which coincided with decreased survival of the cells after ionizing 
radiation. TSA rescued the decrease in protein acetylation and rescued partly the sensitivity 
(chapter 3)49. Therefore, it may be possible that part of the neurodegenerative phenotype 
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observed in Drosophila CoA mutants is because of defects in DNA damage repair pathways, 
causing accumulation of damaged DNA in the brain. Impaired DNA damage repair is associated 
with neurodegeneration and several human diseases such as Ataxia Telangiectasia (ATM), 
AT-like Disorder (AT-LD), Nijmegen Breakage syndrome (NBS) and others59,60. Although it is 
tempting to hypothesize that accumulation of damaged DNA in non-dividing neuronal cells 
leads to cell death and tissue loss, this order of events has not been convincingly demonstrated 
and how DNA damage leads to neurodegeneration is an unresolved puzzle61.
Alternative source for Coenzyme A biosynthesis and its therapeutic use 
for PKAN
In contrast to vitamin-B5, pantethine has a prompt rescue potency in restoring CoA levels and 
reverting acetylation defects in PKAN model systems (Chapter 2 and 3). Moreover, pantethine is 
reported to revert some of the disease phenotypes in other neurodegenerative disease models, 
like in Parkinson disease62,63. However, the possible clinical use of pantethine as a rescuing 
molecule in patients may be limited because pantetheinases or vanins hydrolyse pantethine 
rapidly into cysteamine and pantothenate64-66. Pantetheinases are present ubiquitously in 
humans, especially in the intestine and are also excreted in their active form in the circulation. 
Although pantethine treatment has been shown to have beneficial effects in PANK2 KO mice 
reversing the disease phenotype induced by ketogenic diet, the rescue effect is thought to be 
mainly due to the anti-oxidant role of cysteamine67. In contrast to pantethine, cysteamine did 
not revert the phenotype in the Drosophila PKAN model system (unpublished data). To improve 
pantethine stability and thereby improve its applicability in humans as a rescue agent for PKAN, 
we synthesized a novel pantetheine derivative with a lipophilic thiobutyl triphenylphosphonium 
(TBTP) cation (chapter 4; Figure 2). Moreover, the use of such a lipophilic group will increase the 
chance of effective cell membrane and blood brain barrier permeability and in addition act as 
a selective targeting utility to reach mitochondria. TBTP-pantethine indeed showed increased 
membrane affinity68-70. However, such modification of pantethine did not increase the passive 
membrane permeability as compared to pantethine. Moreover, TBTP coupling did not increase 
the stability of pantethine, as pantetheinases present in fetal calf serum still degraded the TBTP-
pantethine (Chapter 4; Figure 2). Although the identification of PANK-independent alternative 
CoA biosynthesis from pantethine changes the concept of vitamin-B5 being the only substrate 
to form cellular CoA, the instability of pantethine narrows its pharmacological benefits. It also 
clearly indicated the need to explore other possible sources for cellular CoA, which might be 
of therapeutic use to treat PKAN effectively.
CoA has been considered physiologically inert regarding functions outside the cell, 
and this molecule was never envisioned to be able to pass through the cell membrane, 
due to its bulky and highly electronegative nature. However, in an attempt to revert the 
protein acetylation defect induced by PKAN impairment in a Drosophila in vitro model, 
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direct supplementation of CoA in the external cell media revealed a complete rescue effect 
(Chapter 3; Figure 2)49. Moreover, CoA supplementation along with statins has been shown 
to have therapeutic benefit in treating hyperlipidemia71,72. These striking results made us 
 
Figure 2: Over-view of research findings summarized in this thesis. De novo CoA biosynthesis utilizing 
extracellular pantothenate and subsequently processed by pantothenate kinase (PANK), 4’-
phosphopantothenoylcysteine synthetase (PPCS), (R)-4’-phospho-N-pantothenoylcysteine decarboxylase 
(PPCDC), and the bifunctional  4’-phosphopantetheine adenylyltransferase/dephospho-CoA kinase (COASY) to 
form CoA. Pantethine by-passes PANK and is processed by an unknown kinase/protein (X?) contributing to CoA 
biosynthesis (Chapter 2). Cellular CoA levels regulate the protein acetylation homeostasis inside the cell 
(Chapter 3). Pantetheinases or vanin (VNN) degrade both pantetheine and 4-thiobutyl-triphenylphosphonium 
pantetheine to pantothenate in the serum (Chapter 4). External supplemented CoA  is converted into 4’-
phosphopantethine by ecto-nucloetide-pyrophosphatases (ENPP) in the serum, 4’-phosphopantethine crosses 









Figure 2: Over-view of research findings summarized in this thesis. 
De novo CoA biosynthesis utilizing extracellular pantothenate and subsequently processed by 
pantothenate kinase (PANK), 4’-phosphopantothenoylcysteine synthetase (PPCS), (R)-4’-phospho-
N-pantothenoylcysteine decarboxyla e (PPCDC), and the bifunctional  4’-phosphopantetheine 
ade ylyltransferase/dephospho-CoA kinase (COASY) to form CoA. Pantethine by-p sses PANK and is 
processed by an unknown kinase/protein (X?) contributing to CoA biosynthesis (Chapter 2). Cellular CoA 
levels regulate the protein acetylation homeostasis inside the cell (Chapter 3). Pantetheinases or vanin 
(VNN) degrade both pantetheine and 4-thiobutyl-triphenylphosphonium pantetheine to pantothenate 
in the serum (Chapter 4). External supplemented CoA  is converted into 4’-phosphopantethine by ecto-
nucloetide-pyrophosphatases (ENPP) in the serum, 4’-phosphopantethine crosses the plasma membrane 
via passive diffusion and contributes to CoA biosynthesis in a COASY dependent manner (Chapter 5).
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investigate whether such direct effects of CoA exist and if so what is the working mechanism 
behind it. To aid our study in a more precise way, we developed a sensitive chromatography 
method with selectivity for CoA and other related thiol molecules (Chapter 3 and 5).
The evidence presented in Chapter 5 of this thesis demonstrated that cells and organisms 
are indeed able to acquire CoA not only via the uptake of vitamin B5 but also via the direct 
supplementation of exogenous CoA. Our experimental data showed that CoA needs to be 
hydrolyzed extracellularly by exo-enzymes into 4’-phosphopantetheine (PPanSH), which is a 
biologically stable molecule and is taken up by cells. Intracellularly, PPanSH is converted back 
to CoA by the bifunctional enzyme COASY. This newly identified non-canonical source for CoA 
is independent of PANK and PPCDC. As described in Chapter 5, external supplementation of 
CoA, but not vitamin B5, rescued various phenotypes induced by impaired PANK and PPCDC in 
Drosophila model systems. The rescue effect of CoA in a validated dPANK/fbl null mutant and in a 
severely affected dPPCDC Drosophila mutant, but not dCOASY mutants, clearly revealed a potent 
working mechanism of CoA supplied via fly food. We also provided evidence that this mechanism 
is prevalent among diverse eukaryotic organisms and cells, including C.elegans, human cells and 
in mice. The proposed mechanism thus suggests a net flow of CoA via PPanSH between cells 
and between membrane-bound cellular compartments. Moreover, the rescue potency of CoA 
in reverting the female sterility in dPPCDC mutants clearly supports that the beneficial effect 
of PPanSH obtained from CoA is far reaching within an organism and is crossing various cellular 
barriers. In contrast to the instability of pantethine in human serum, PPanSH obtained via external 
CoA is found to be stable which indicates its promises to be an effective non-canonical substrate 
for CoA biosynthesis obtained via the circulation. The confirmation of endogenous PPanSH in 
mouse serum by both HPLC and mass spectrometry, substantiates the natural occurrence of this 
alternative source route in higher eukaryotes for CoA biosynthesis (Chapter 5). Exogenous CoA 
or PPanSH might not be beneficial for CoPAN therapy, as this alternative route requires active 
COASY. Nevertheless, CoA or PPanSH might provide a promising treatment possibility for PKAN.
Concluding remarks and perspectives
With the knowledge that CoA is not only a key molecule in metabolism playing a role in 
over 100 metabolic reactions, but that CoA also modulates the epigenome and at least 
activates one specific kinase (CaMKII)9, the influence of this molecule in health and disease 
is most likely larger than ever anticipated. Further detailed investigation is yet required 
to understand whether impaired metabolism, abnormal protein acetylation or impaired 
activation of CaMKII or possible other proteins or a combinatorial effect causes the specific 
disease characteristics of PKAN and CoPAN. It is also important to understand the effects of 
mutations of PANK2 and COASY with regards to their activity in both CoA biosynthesis but also 
in mitochondrial structural integrity. Since not all the mutations leading to PKAN correlates 
with loss of PANK2 activity73,74 and with the use of CoPAN patient fibroblasts evidence was 
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presented that CoA is still being produced31, mitochondrial dysfunction could be one of the 
leading cause of neurodegeneration. Hence, it is necessary for the future to perform further 
in-depth experiments to reveal precisely the link between the multifaceted influence of CoA 
and its related diseases, including PKAN and CoPAN.
It is also important to elucidate additional alternative possible ways to manipulate cellular 
CoA levels. In vitro studies have indicated that small molecules like palmitoyl carnitine and 
oleyl carnitine can activate PANK75,76. However, this has never been confirmed in vivo. 
Exploiting such small molecules as activators or repressors will be useful in our research to 
find possibilities to be able to manipulate CoA levels and this knowledge will be helpful to 
understand the role of CoA in cellular physiology and may lead to possible ways to treat PKAN 
and CoPAN. High throughput screening to identify regulators of the promoters of the genes 
coding for CoA biosynthesis enzymes could also be a useful approach77. Moreover, the use of 
pantethine or TBTP-pantetheine as novel alternative substrates for CoA production can be 
substantiated by combining them with pantetheinase inhibitors78,79 to achieve clinical benefit. 
Moreover, the use of HDAC inhibitors like TSA alone or in addition to pantethine or 
pantetheine derivatives might also provide efficient benefits compared to treatment with 
pantethine or pantetheine derivatives only. The new breakthrough in deciphering the working 
mechanism of externally supplemented CoA via PPanSH has broadened the scope of CoA 
research in both basic cell biology and in disease pathophysiology. Our experimental proof 
of PPanSH as a crucial molecule in reverting the PKAN phenotype may be a physiologically 
relevant process because we could detect endogenous PPanSH in fresh mouse serum. In 
clinical studies, CoA alone or with the addition of statins showed a beneficial effect in lowering 
plasma triglyceride levels in patients with moderate dyslipidemia and thereby acted as a 
natural hypolipidemic drug with no obvious adverse effect detected71,72. Our findings suggest 
that the above mentioned CoA mode of action in hyperlipidemia is via PPanSH. Recently, the 
de novo CoA biosynthesis pathway in microbes also obtained interest because of the fact 
that small molecules can be developed acting as novel antimicrobial drugs by specifically 
targeting the microbial CoA biosynthesis enzymes80,81. This is possible because prokaryotic 
CoA biosynthesis pathway enzymes vary in their sequences and structural integrity compared 
to the eukaryotic enzymes80-82. In addition, the development of CoA/PPanSH antimetabolities 
that can selectively inhibit the activity of parasite and microbial CoA biosynthesis enzymes 
and thereby reduce CoA levels and/or interfere with the species-specific CoA dependent 
processes will be promising to treat parasite and microbial infections80,81. Overall, this thesis 
summarized the diverse influence/function of CoA, apart from its most classically known 
metabolic role. It also reports about in-depth experimental outcomes to understand the 
role of impaired de novo CoA biosynthesis in cellular physiology. In addition, the finding of 
a possible alternative source for CoA biosynthesis like pantethine, PPanSH, and CoA provides 
a promising start to design a therapy for PKAN and other CoA related diseases. 
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